A Form 144 notice of proposed sale was filed on October 30, 2026, by Sanj K Patel, an officer and director of Kiniksa Pharmaceuticals International, plc, covering 553,794 Class A Ordinary Shares to be sold through Charles Schwab & Co., Inc.

Key Highlights

  • Proposed sale size: 553,794 Class A Ordinary Shares with an aggregate market value of $51,571,367.00, according to the filing.
  • Seller identity: Patel Sanj K, listed as both an officer and a director of Kiniksa Pharmaceuticals International, plc.
  • Broker named: Charles Schwab & Co., Inc., located at 3000 Schwab Way, Westlake, TX 76262.
  • Shares outstanding: The filing reports 48,836,965 Class A Ordinary Shares outstanding.
  • Approximate date of sale: October 30, 2026, on the NASDAQ exchange.
  • Rule 10b5-1 plan: The filing indicates a trading plan or instruction was adopted on July 30, 2026.
  • Account: The securities are disclosed as held and to be sold in the Anglia Revocable Trust; the notice is signed by Sanj K Patel TTEE.

Acquisition Background and Security Details for the Proposed Kiniksa Sale

According to the filing, the 553,794 Class A Ordinary Shares proposed for sale were acquired through three separate transactions. First, 51,794 shares were acquired on March 16, 2022, via a restricted stock lapse, with the nature of payment listed as equity compensation. Second, 125,000 shares were acquired on October 15, 2015, as founders shares, with no monetary consideration indicated. Third, 377,000 shares were acquired on October 30, 2026, through an employee stock option exercise, with the nature of payment described as broker payment for cashless exercise.

The filing's remarks section states that "the shares reported in this filing were acquired and paid for between 03/16/2022 and 09/02/2023 and were sold in the Anglia Revocable Trust," and notes that "options in this filing may be sold over various dates." The issuer is identified as Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA), with its address listed as 105 Piccadilly, Second Floor, London, United Kingdom, W1J 7NJ, and SEC file number 001-38492.

The filing reports no securities sold by Patel during the past three months. By signing the Form 144, the filer represented, as of the plan adoption date of July 30, 2026, that no material adverse information regarding the current and prospective operations of the issuer was known to the filer that had not been publicly disclosed.

What Was Disclosed

Sanj K Patel, an officer and director of Kiniksa Pharmaceuticals International, plc, filed a Form 144 on October 30, 2026, disclosing a proposed sale of 553,794 Class A Ordinary Shares valued at $51,571,367.00, held in the Anglia Revocable Trust, through Charles Schwab & Co., Inc. on NASDAQ.